Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.35 |
| ▸ | PRKACA | P17612 | 5/20 | 0.35 |
| ▸ | GSK3A | P49840 | 5/20 | 0.35 |
| ▸ | GSK3B | P49841 | 5/20 | 0.35 |
| ▸ | PRKX | P51817 | 5/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | PRKG1 | Q13976 | 4/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.35 |
| ▸ | SGK2 | Q9HBY8 | 4/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.35 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.35 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445137 | 1.00 | MMP12 (0.36) | MMP12MMP13ROCK1ROCK2PRKACA | |
| SCHEMBL6278607 | 0.91 | HDAC8 (0.36) | ROCK1ROCK2PRKACAGSK3AGSK3B | |
| SCHEMBL7604810 | 0.87 | MMP2 (0.34) | MMP3MMP2MMP1HDAC8 | |
| SCHEMBL7604813 | 0.87 | MMP2 (0.34) | MMP3MMP2MMP1HDAC8 | |
| SCHEMBL7454036 | 0.86 | MMP13 (0.38) | MMP12MMP13MMP3MMP9MMP2 | |
| SCHEMBL7462334 | 0.86 | MMP13 (0.38) | MMP12MMP13MMP3MMP9MMP2 | |
| SCHEMBL7454042 | 0.86 | MMP13 (0.38) | MMP12MMP13MMP3MMP9MMP2 | |
| SCHEMBL7604817 | 0.86 | MMP13 (0.38) | MMP12MMP13MMP3MMP9MMP2 | |
| SCHEMBL7454170 | 0.84 | MMP2 (0.43) | MMP3MMP2MMP1 | |
| SCHEMBL7454159 | 0.84 | MMP2 (0.43) | MMP3MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | claimed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | claimed |
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0937042-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | MMP12 27/4885MMP13 7/4885ROCK1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.